Brief: Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial
18/05/2026 21:07
May 18 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY TO PRESENT COMPLETE WEEK 96 DATA FROM PHASE 2 SOLSTICE CLINICAL TRIAL IN HEPATITIS DELTA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONGRESS 2026 Source text: ID:nBw5SmxHta Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO